表紙:末期腎不全(ESRD):パイプライン製品の分析
市場調査レポート
商品コード
257819

末期腎不全(ESRD):パイプライン製品の分析

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genitourinary Disorders) - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 44 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.26円
末期腎不全(ESRD):パイプライン製品の分析
出版日: 2021年09月30日
発行: Global Markets Direct
ページ情報: 英文 44 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

末期腎不全(ESRD)とは、腎臓の機能が完全に、あるいは殆ど喪失した状態のことを指します。主な症状として、排尿不全や倦怠感、頭痛、食欲不振、悪心嘔吐、骨の痛み、意識混濁、集中力低下などが挙げられます。主なリスク要因には、多発性嚢胞腎疾患やアルポート症候群、間質性腎炎、一部の自己免疫障害(狼瘡など)があります。また、主な治療法には透析・腎移植などがあります。

当レポートでは、世界各国での末期腎疾患(DSRD)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果をお届けします。

目次

イントロダクション

  • 分析範囲

末期腎疾患の概要

治療薬の開発

  • 末期腎疾患向けパイプライン製品:概要
  • 企業別のパイプライン
  • 企業で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

末期腎疾患治療薬の開発に従事している企業

  • BLR Bio LLC
  • CTI BioPharma Corp
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Prolong Pharmaceuticals LLC
  • VESSL Therapeutics Ltd

薬剤のプロファイル

末期腎疾患治療薬:休止状態のプロジェクト

末期腎疾患治療薬:開発が中止された製品

付録

図表一覧

図表

List of Tables

List of Tables

  • Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Acacia Pharma Ltd, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Aronora Inc, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Bayer AG, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BioAegis Therapeutics Inc, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Daiichi Sankyo Co Ltd, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Ionis Pharmaceuticals Inc, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by KidneyCure Ltd, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by VESSL Therapeutics Ltd, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
目次
Product Code: GMDHC13082IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease - Drugs In Development, 2021, provides an overview of the End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide End-Stage Kidney Disease - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 1, 1, 1 and 1 respectively.

End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development
  • Acacia Pharma Ltd
  • Aronora Inc
  • Bayer AG
  • BioAegis Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Ionis Pharmaceuticals Inc
  • KidneyCure Ltd
  • VESSL Therapeutics Ltd
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles
  • 3DAN-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AB-023 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • amisulpride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for Peripheral Arterial Disease and End-Stage Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IONIS-FXILRx - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • osocimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit TDO2 for End-Stage Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 19, 2021: Aronora reports positive topline data from phase 2 study of AB023 in hemodialysis patients
  • Dec 02, 2020: Aronora announces clinical data to be presented at the 62nd American Society of Hematology Annual Meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer